Allogeneic IgG combined with dendritic cell stimuli induce antitumour T-cell immunity

Abstract

While cancers grow in their hosts and evade host immunity through immunoediting and immunosuppression1–5, tumors are rarely transmissible between individuals. Much like transplanted allogeneic organs, allogeneic tumors are reliably rejected by host T cells, even when the tumor and host share the same major histocompatibility complex (MHC) alleles, the most potent determinants of transplant rejection6–10. How such tumor-eradicating immunity is initiated remains unknown, though elucidating this process could provide a roadmap for inducing similar responses against naturally arising tumors. We found that allogeneic tumor rejection is initiated by naturally occurring tumor-binding IgG antibodies, which enable dendritic cells (DC) to internalize tumor antigens and subsequently activate tumor-reactive T cells. We exploited this mechanism to successfully treat autologous and autochthonous tumors. Either systemic administration of DC loaded with allogeneic IgG (alloIgG)-coated tumor cells or intratumoral injection of alloIgG in combination with DC stimuli induced potent T cell mediated anti-tumor immune responses, resulting in tumor eradication in mouse models of melanoma, pancreas, lung and breast cancer. Moreover, this strategy led to eradication of distant tumors and metastases, as well as the injected primary tumors. To assess the clinical relevance of these findings, we studied antibodies and cells from patients with lung cancer. T cells from these patients responded vigorously to autologous tumor antigens after culture with alloIgG-loaded DC, recapitulating our findings in mice. These results reveal that tumor-binding alloIgG can induce powerful anti-tumor immunity that can be exploited for cancer immunotherapy.

Toll-like receptor 3-induced immune response by poly(D,L-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy

“…27,30 We used monoclonal antibody 2.43 for CD8 + T cell depletion. One week after tumor cell injection, the mice were randomly allocated into the following groups (n=6 mice per group): (1) DCs only as a control, (2) DCs treated with PLGA (OVA + poly I:C)-NPs with CD8 + T cell depletion, and (3) DCs treated with PLGA (OVA)-NPs.…”

IL-33 delays metastatic peritoneal cancer progression inducing an allergic microenvironment

“…We depleted B cells by intraperitoneally injecting 300μg of anti-mouse CD19 (1D3, BioXcell) and 300μg of anti-mouse B220 (RA3.3A1/6.1, BioXcell). 54 …”

Targeting lymphoma with precision using semisynthetic anti-idiotype peptibodies

“…Peptibody-mediated phagocytosis of tumor cells and presentation of tumor antigens by APCs such as macrophages or dendritic cells could also promote an adaptive immune response that might increase the probability of obtaining a durable remission (27)(28)(29). Because phagocytosis would be restricted to tumor cells that express tumor-specific neoantigens, peptibodies might promote a more robust adaptive immune response than antibodies against tumor-associated antigens such as CD20 or other agents that mediate less than tumor-specific cell death or phagocytosis.…”